Erratum

In “Factors Associated with Viral Rebound in HIV-1-Infected Individuals Enrolled in a Therapeutic HIV-1 gag Vaccine Trial,” by Li et al. (J Infect Dis. (2011) 203 (7): 976–983), the title of Table 2 was inadvertently changed and some data were incorrect due to errors made without the authors' knowledge. A corrected version of the table is shown below.

Table 2.

Number of log₁₀ Gag-Specific CD4+ IFN-γ-Producing Cells per Million Lymphocytes at Study Week 38 Categorized by HLA Allele Grouping and Treatment Arm

		Treatment arm, median [IQR]a
HLA group	Pb	Vaccine	Placebo	Pc
Protective	.10	2.21 [± 0.70] (n=31)	2.25 [± 0.43] (n=5)
Neutral		2.40 [± 0.40] (n=36)	2.11 [± 0.51] (n=27)	.003
Unfavorable		2.1 [± 0.51] (n=5)	2.17 [± 1.40] (n=4)

NOTE. ^aIQR, interquartile range.

^bComparison of the vaccine/protective and vaccine/neutral subgroups.

^cComparison of the vaccine/neutral and placebo/neutral subgroups.